Company Introduction

Immunwork, Inc. was founded in October 2014. We focus on the research, development, and commercialization of a series of new drugs, which have been created based on our proprietary technology platform, to treat multiple types of cancer, diabetes, pathological clots, and other selected severe diseases.
Our vision is to develop new drugs carrying both targeting and effector functions, for increased efficacy and reduced toxicity.
Our technology platform enables us to design a class of new pharmaceuticals, which we term “T-E pharmaceuticals”. These new pharmaceuticals contain two functional moieties: a targeting (T) moiety and an effector (E) moiety.

Brief description of main products or services 

Immunwork has developed a series of drug candidates focusing on unmet medical needs.  Immunwork also has solid international patent portfolio with over 50 grated patents in US, Japan, Singapore, Australia, and Taiwan. Over 50 more patent applications are on-going.

The drug-design platform can be employed for constructing antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), long-acting peptide drugs conjugated with fatty acid (FA) bundle, and other pharmaceutical configurations. Five product candidates have been identified, including long-acting octreotide (TE-8214) for treating neuroendocrine tumors (NETs) and related diseases, long-acting insulin (TE-8024) for treating type I & II diabetes, long-acting GLP-1 (TE-8105) for treating type II diabetes, anti-CD38 ADC carrying lenalidomide bundles (TE-1146) for treating multiple myeloma, and fibrin-targeting tPA (TE-6168) for treating pathological clots. These product candidates are planned to apply for IND with 5 product candidates during 2022-2023.